Eisai Inc will present 3 posters during the 10th annual Clinical Trials on Alzheimer’s Disease (CTAD) meeting, highlighting data on ways to screen for cognitive impairment and sleep disorders associated with mild to moderate stages of Alzheimer’s disease (AD) dementia.
“Our poster on sleep-wake patterns includes baseline data derived by wrist actigraphy from a phase 2 study of a novel treatment for irregular sleep-wake rhythm disorder (ISWRD) in Alzheimer’s dementia patients,” says Lynn Kramer, MD, chief clinical officer and chief medical officer, Neurology Business Group, Eisai, in a release. “Through new and continued research, we aim to further understand how treating ISWRD can impact the quality of life for patients and their families.”
Two other posters presented at the meeting will look the use of the International Shopping List Test (ISLT) as an objective cognitive assessment to select individuals with early Alzheimer’s disease in clinical trials, including Eisai’s Phase 3 trial of elenbecestat (E2609).
The following data will be presented during poster sessions at the meeting:
- Characteristics of Sleep and Wakefulness Measured with Actigraphy in Patients with Irregular Sleep-Wake Rhythm Disorder and Alzheimer’s Disease
- Use of the International Shopping List Test as the objective assessment of cognitive impairment to identify subjects with early Alzheimer’s disease in the Eisai elenbecestat Mission AD phase 3 clinical trials
- Utility of the International Shopping List Test for detection of memory impairment associated with prodromal and early Alzheimer’s disease in clinical trials
Eisai is investigating the safety and efficacy of lemborexant in patients aged 60 to 90 with ISWRD and mild to moderate AD dementia. Discovered by Eisai, lemborexant is a dual orexin receptor antagonist that competitively binds to the 2 subtypes of orexin receptors. The orexin system is a major regulator of the sleep-wake system. Lemborexant is being jointly developed by Eisai and Purdue Pharma LP.
ISWRD is a circadian rhythm sleep disorder characterized by numerous sleep bouts throughout the 24-hour period, disrupted nighttime sleep, and changing sleep and wake patterns from day to day. It is a common comorbid condition in AD and other dementias, appears early in the course of disease, and is associated with many of the behavioral disturbances in AD/dementia patients (eg, agitation, restlessness, wandering).
Elenbecestat is Eisai’s in-house discovered beta amyloid cleaving enzyme (BACE) inhibitor and is being jointly developed by Eisai and Biogen in 2 global phase 3 clinical studies (known as MISSION AD1 and MISSION AD2) as a potential treatment for early AD.
These abstracts discusses investigational uses of agents in development and are not intended to convey conclusions about efficacy or safety. There is no guarantee that any investigational uses of such products will successfully complete clinical development or gain FDA approval.